Pricing Log in Create free account

SELLAS Life Sciences Group, Inc. (SLS) vs Zenas BioPharma, Inc. (ZBIO)

SELLAS Life Sciences Group, Inc. and Zenas BioPharma, Inc. are both Biotechnology companies. SELLAS Life Sciences Group, Inc. and Zenas BioPharma, Inc. are of similar size ($1.7B and $1.6B). SELLAS Life Sciences Group, Inc. has the higher net margin (0.00% vs −763.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, SELLAS Life Sciences Group, Inc. leads on 9 and Zenas BioPharma, Inc. on 5.

Valuation

Metric SLS ZBIO Biotechnology median
P/E n/m n/m 10.60
P/S 149.37 26.29 9.40
P/B 11.39 8.79 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 136.22 23.52 9.02
Earnings yield (2.53%) (33.38%) (32.88%)
Free cash flow yield (2.45%) (13.01%) (23.13%)

Profitability

Metric SLS ZBIO Biotechnology median
Gross margin 0.00% 100.00% 68.51%
Operating margin 0.00% (741.41%) 0.00%
Net margin 0.00% (763.11%) 0.00%
Free cash flow margin 0.00% (342.02%) 0.00%
Return on equity (39.63%) (265.11%) (51.96%)
Return on assets (36.54%) (108.66%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric SLS ZBIO Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) 50.00% 29.04% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric SLS ZBIO Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 18.83 9.42 4.97
Net debt to EBITDA 2.54 0.69 1.01

Dividend

Metric SLS ZBIO Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric SLS ZBIO Biotechnology median
Market cap 1.59b 1.69b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack